參與肺癌靶向耐藥的IncRNAs的作用及其機制

打開文本圖片集

中圖分類號：R979.1；R966 文獻(xiàn)標(biāo)志碼：A 文章編號： 1000-5013（2025）04-0369-10

Role of LncRNAs in Targeted Drug Resistance in Lung Cancer and Their Mechanisms

YANG Suxin 1，2 ，MA

（1.School of Medicine，Huaqiao University，Xiamen 36lo21，China; 2.School of Sociology，Universidad 28o4o，Spain）

Abstract：The roles and mechanisms of long non-coding RNAs （lncRNAs） involved in targeted drug resistance in lung cancer were analyzed comprehensively，elucidating multiple biomarkers for treating lung cancer resistance.By reviewing relevant literature in recent years，the involvement in cisplatin （DDP）resistance in lung cancer，targeted epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs）resistance，targeted anaplastic lymphoma kinase tyrosine kinase inhibitors （ALK-TKIs） resistance，and various long non-coding RNAs （lncRNAs） resistant to immunotherapy were summarized，and its role and contribution in reversing drug resistance in lung cancer were analyzed. The results show that among the lncRNAs associated with EGFR-TKIs targeted resistance，LINCo046O not only regulates gefitinib resistance through activation of the miR-338-3p/SMC4 pathway， but also plays a crucial role in resistance to osimertinib. Additionally，lung adenocarcinoma metastasis-associated transcript 1 has been shown to affect immune resistance by modulating the expression of major histocompatibility complex proteins and programmed death-ligand 1，highlighting its potential as a key therapeutic target for improving the outcomes of immunotherapy in lung cancer.

Keywords：long non-coding RNAs （lncRNAs）； lung cancer； cisplatin resistance; targeted drug resistance;molecular mechanism

雖然肺癌化療和靶向治療研究已經(jīng)取得了突破性進(jìn)展，并顯著地改善了患者預(yù)后，但腫瘤多藥耐藥（multi-drug resistance，MDR）導(dǎo)致的化療失敗和復(fù)發(fā)依舊是肺癌治療中的一大難題。（剩余20964字）